Food and Drug Administration, U.S. Department of Health and Human Services - December 2, 1997
Researchers from FDA's Center for Biologics Evaluation and Review (CBER) and the University of Sydney discovered how a protein known as CD26 that is present on the surface of certain white blood cells influences chemokines and either disables or activates them.
The FDA scientists propose that new therapies may be developed that change the impact that CD26 has on chemokines. These new treatments may help prevent infection with HIV and other pathogens, as well as treat or prevent other diseases in which chemokines have a major role.
The main authors of the study at FDA are Drs. Tamas Oravecz and Michael Norcross. At the University of Sydney, Dr. Mark Gorrell is the author.
971202
FD971201
SOURCE: Food and Drug Administration (FDA).
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .